1887

Abstract

G to A hypermutation of (HBV) and retroviruses appears as a result of deamination activities of host APOBEC proteins and is thought to play a role in innate antiviral immunity. Alpha and gamma interferons (IFN- and -) have been reported to upregulate the transcription of APOBEC3G, which is known to reduce the replication of HBV. We investigated the number of hypermutated genomes under various conditions by developing a quantitative measurement. The level of hypermutated HBV in a HepG2 cell line, which is semi-permissive for retrovirus, was 2.3 in 10 HBV genomes, but only 0.5 in 10 in permissive Huh7 cells. The level of APOBEC3G mRNA was about ten times greater in HepG2 cells than in Huh7 cells. Treatment of HepG2 cells with either IFN- or - increased the transcription of APOBEC3G and hypermutation of HBV. These mRNAs and hypermutation of HBV genomes were induced more prominently by IFN- than by IFN-. Both IFNs decreased the number of replicative intermediate of HBV. Overexpression of APOBEC3G reduced the number of replicative intermediate of HBV and increased hypermutated genomes 334 times, reaching 968 in 10 genomes. Deamination-inactive APOBEC3G did not induce hypermutation, but reduced the virus equally. Our results suggest that APOBEC3G, upregulated by IFNs, has a dual effect on HBV: induction of hypermutation and reduction of virus synthesis. The effect of hypermutation on infectivity should be investigated further.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.82319-0
2007-02-01
2024-03-29
Loading full text...

Full text loading...

/deliver/fulltext/jgv/88/2/432.html?itemId=/content/journal/jgv/10.1099/vir.0.82319-0&mimeType=html&fmt=ahah

References

  1. Abu-Daya A., Brown P. M., Fox K. R. 1995; DNA sequence preferences of several AT-selective minor groove binding ligands. Nucleic Acids Res 23:3385–3392 [CrossRef]
    [Google Scholar]
  2. Bonvin M., Achermann F., Greeve I., Stroka D., Keogh A., Inderbitzin D., Candinas D., Sommer P., Wain-Hobson S. other authors 2006; Interferon-inducible expression of APOBEC3 editing enzymes in human hepatocytes and inhibition of hepatitis B virus replication. Hepatology 43:1364–1374 [CrossRef]
    [Google Scholar]
  3. Bruix J., Llovet J. M. 2003; Hepatitis B virus and hepatocellular carcinoma. J Hepatol 39 (Suppl. 1):S59–S63 [CrossRef]
    [Google Scholar]
  4. Colonna M., Krug A., Cella M. 2002; Interferon-producing cells: on the front line in immune responses against pathogens. Curr Opin Immunol 14:373–379 [CrossRef]
    [Google Scholar]
  5. Ganem D., Schneider R. 2001; Hepadnaviridae : the viruses and their replication. In Fields Virology , 4th edn. pp  2923–2969 Edited by Knipe D. M., Howley P. M. Baltimore: Lippincott Williams & Wilkins;
    [Google Scholar]
  6. Ganem D., Prince A. M. 2004; Hepatitis B virus infection - natural history and clinical consequences. N Engl J Med 350:1118–1129 [CrossRef]
    [Google Scholar]
  7. Grandvaux N., tenOever B. R., Servant M. J., Hiscott J. 2002; The interferon antiviral response: from viral invasion to evasion. Curr Opin Infect Dis 15:259–267 [CrossRef]
    [Google Scholar]
  8. Gunther S., Sommer G., Plikat U., Iwanska A., Wain-Hobson S., Will H., Meyerhans A. 1997; Naturally occurring hepatitis B virus genomes bearing the hallmarks of retroviral G→A hypermutation. Virology 235:104–108 [CrossRef]
    [Google Scholar]
  9. Harris R. S., Bishop K. N., Sheehy A. M., Craig H. M., Pertersen-Mahrt S. K., Watt I. N., Neuberger M. S., Malim M. H. 2003; DNA deamination mediates innate immunity to retroviral infection. Cell 113:803–809 [CrossRef]
    [Google Scholar]
  10. Janini M., Rogers M., Birx D. R., McCutchan F. E. 2001; Human immunodeficiency virus type 1 DNA sequences genetically damaged by hypermutation are often abundant in patient peripheral blood mononuclear cells and may be generated during near-simultaneous infection and activation of CD4(+) T cells. J Virol 75:7973–7986 [CrossRef]
    [Google Scholar]
  11. Jarmuz A., Chester A., Bayliss J., Gisbourne J., Dunham I., Scott J., Navaratnam N. 2002; An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics 79:285–296 [CrossRef]
    [Google Scholar]
  12. Kobayashi M., Takaori-Kondo A., Shindo K., Abudu A., Fukunaga K., Uchiyama T. 2004; APOBEC3G targets specific virus species. J Virol 78:8238–8244 [CrossRef]
    [Google Scholar]
  13. Lecossier D., Bouchonnet F., Clavel F., Hance A. J. 2003; Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science 300:1112 [CrossRef]
    [Google Scholar]
  14. Mangeat B., Turelli P., Caron G., Friedli M., Perrin L., Trono D. 2003; Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424:99–103 [CrossRef]
    [Google Scholar]
  15. Newman E. N., Holmes R. K., Craig H. M., Klein K. C., Lingappa J. R., Malim M. H., Sheehy A. M. 2005; Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Curr Biol 15:166–170 [CrossRef]
    [Google Scholar]
  16. Noguchi C., Ishino H., Tsuge M., Fujimoto Y., Imamura M., Takahashi S., Chayama K. 2005; G to A hypermutation of hepatitis B virus. Hepatology 41:626–633 [CrossRef]
    [Google Scholar]
  17. Norder H., Courouce A. M., Magnius L. O. 1994; Complete genomes, phylogenetic relatedness, and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes. Virology 198:489–503 [CrossRef]
    [Google Scholar]
  18. Peng G., Lei K. J., Jin W., Greenwell-Wild T., Wahl S. M. 2006; Induction of APOBEC3 family proteins, a defensive maneuver underlying interferon-induced anti-HIV-1 activity. J Exp Med 203:41–46 [CrossRef]
    [Google Scholar]
  19. Rosler C., Kock J., Malim M. H., Blum H. E., von Weizsacker F. 2004; Comment on ‘Inhibition of hepatitis B virus replication by APOBEC3G’. Science 305:1403 (author reply 1403 [CrossRef]
    [Google Scholar]
  20. Rosler C., Kock J., Kann M., Malim M. H., Blum H. E., Baumert T. F., von Weizsacker F. 2005; APOBEC-mediated interference with hepadnavirus production. Hepatology 42:301–309
    [Google Scholar]
  21. Samuel C. E. 2001; Antiviral actions of interferons. Clin Microbiol Rev 14:778–809 [CrossRef]
    [Google Scholar]
  22. Seeger C., Mason W. S. 2000; Hepatitis B virus biology. Microbiol Mol Biol Rev 64:51–68 [CrossRef]
    [Google Scholar]
  23. Sheehy A. M., Gaddis N. C., Choi J. D., Malim M. H. 2002; Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418:646–650 [CrossRef]
    [Google Scholar]
  24. Shindo K., Takaori-Kondo A., Kobayashi M., Abudu A., Fukunaga K., Uchiyama T. 2003; The enzymatic activity of CEM15/Apobec-3G is essential for the regulation of the infectivity of HIV-1 virion but not a sole determinant of its antiviral activity. J Biol Chem 278:44412–44416 [CrossRef]
    [Google Scholar]
  25. Shirakawa K., Takaori-Kondo A., Kobayashi M., Tomonaga M., Izumi T., Fukunaga K., Sasada A., Abudu A., Miyauchi Y. other authors 2006; Ubiquitination of APOBEC3 proteins by the Vif-Cullin5-ElonginB-ElonginC complex. Virology 344:263–266 [CrossRef]
    [Google Scholar]
  26. Skalka A. M., Goff S. P. 1993 Reverse Transcriptase Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press;
    [Google Scholar]
  27. Summers J., Mason W. S. 1982; Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate. Cell 29:403–415 [CrossRef]
    [Google Scholar]
  28. Suspene R., Guetard D., Henry M., Sommer P., Wain-Hobson S., Vartanian J. P. 2005a; Extensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine deaminases in vitro and in vivo. Proc Natl Acad Sci U S A 102:8321–8326 [CrossRef]
    [Google Scholar]
  29. Suspene R., Henry M., Guillot S., Wain-Hobson S., Vartanian J. P. 2005b; Recovery of APOBEC3-edited human immunodeficiency virus G→A hypermutants by differential DNA denaturation PCR. J Gen Virol 86:125–129 [CrossRef]
    [Google Scholar]
  30. Tanaka Y., Marusawa H., Seno H., Matsumoto Y., Ueda Y., Kodama Y., Endo Y., Yamauchi J., Matsumoto T. other authors 2006; Anti-viral protein APOBEC3G is induced by interferon- α stimulation in human hepatocytes. Biochem Biophys Res Commun 341:314–319 [CrossRef]
    [Google Scholar]
  31. Tsuge M., Hiraga N., Takaishi H., Noguchi C., Oga H., Imamura M., Takahashi S., Iwao E., Fujimoto Y. other authors 2005; Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis B virus. Hepatology 42:1046–1054 [CrossRef]
    [Google Scholar]
  32. Turelli P., Jost S., Mangeat B., Trono D. 2004a; Response to comment of ‘Inhibition of hepatitis B virus replication by APOBEC3G’. Science 305:1403b [CrossRef]
    [Google Scholar]
  33. Turelli P., Mangeat B., Jost S., Vianin S., Trono D. 2004b; Inhibition of hepatitis B virus replication by APOBEC3G. Science 303:1829 [CrossRef]
    [Google Scholar]
  34. Wieland S., Thimme R., Purcell R. H., Chisari F. V. 2004a; Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci U S A 101:6669–6674 [CrossRef]
    [Google Scholar]
  35. Wieland S. F., Spangenberg H. C., Thimme R., Purcell R. H., Chisari F. V. 2004b; Expansion and contraction of the hepatitis B virus transcriptional template in infected chimpanzees. Proc Natl Acad Sci U S A 101:2129–2134 [CrossRef]
    [Google Scholar]
  36. Wieland S. F., Eustaquio A., Whitten-Bauer C., Boyd B., Chisari F. V. 2005; Interferon prevents formation of replication-competent hepatitis B virus RNA-containing nucleocapsids. Proc Natl Acad Sci U S A 102:9913–9917 [CrossRef]
    [Google Scholar]
  37. Wright T. L., Lau J. Y. 1993; Clinical aspects of hepatitis B virus infection. Lancet 342:1340–1344 [CrossRef]
    [Google Scholar]
  38. Zhang H., Yang B., Pomerantz R. J., Zhang C., Arunachalam S. C., Gao L. 2003; The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 424:94–98 [CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.82319-0
Loading
/content/journal/jgv/10.1099/vir.0.82319-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error